The Medscape Journal of Medicine continues publication of MedGenMed beginning in January 2008. MedGenMed: Medscape General Medicine was the original open-access peer-reviewed general medical ...

Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy aloneTopline data from the 450 µg/kg cohort, further strengthens the ...

Think back to your teenage years. What decisions do you wish you could take back? Skipping class? Never trying out for the varsity basketball team? Your prom date? In hindsight, those choices were ...

Introduction: In this study, we explored the effectiveness and safety of the immune checkpoint inhibitor camrelizumab in combination with chemotherapy for the treatment of cervical cancer by ...

Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy alone Topline data from the 450 µg/kg cohort, further strengthens the ...